Nav: Home

Future therapeutics: Drugs that stop free radicals at their source

October 04, 2016

Go to any health food store and you're likely to see shelves crowded with antioxidants that promise to quell damage from free radicals, which are implicated in a myriad of human diseases and in the aging process itself. The problem is that antioxidants have failed to show benefits in several clinical trials and there is even some evidence they could be counterproductive.

Buck professor Martin Brand, PhD thinks that the current approaches to free radicals may fail because they apply a "sledgehammer" to a complex metabolic process that provides essential energy to our cells. "Rather than a sledgehammer that seeks to decrease the effects of free radicals, we've developed a scalpel that allows us to stop them from being produced in the first place," he said. The results of the research will be published online in Cell Metabolism.

Free radicals are produced in the mitochondria - the energy-converting organelles which are abundant in almost every type of human cell. Highly-reactive free radicals, which oxidize cell constituents (hence the use of antioxidants), are spun-off as a normal byproduct of cellular bioenergetics; it's a process that appears to go up when cells are stressed, something Brand says can occur with aging and disease.

A chain of electron transporters within the mitochondria is involved in the production of both free radicals and the chemical energy essential for life. The challenge has been to stop the free radicals without shutting down the cell's ability to release energy. Brand and his colleagues at the Genomics Institute of the Novartis Research Foundation (GNF) did that by painstakingly screening 635,000 small molecules in GNF's academic library to single out the few that blocked free radical production at a specific site thought to be a major source of free radicals in the electron transport chain.

In this latest research, they demonstrated the potency and specificity of the successful molecules and tested their effects in cell culture, isolated hearts, and live models of disease. Brand says the compounds dramatically protected against reperfusion injury in a mouse heart model of ischemia. "Most of the lasting damage from heart attacks comes when blood flow is restored to the heart muscle," he said. "These compounds have great potential as therapeutic leads for drugs that could be given following a heart attack or after stents have been inserted to open blocked coronary blood vessels."

In addition, the molecules diminished oxidative damage in brain cells cultured in low levels of oxygen; they also diminished stem cell hyperplasia in the intestines of fruit flies. Brand says the study offers researchers a way to test the hypothesis that oxidative damage is specifically linked to disease. "For the first time we can test the effects of free radical damage in Alzheimer's, Parkinson's, cancer, type 2 diabetes, macular degeneration - you name it," he said. "It gives you a target, and a drug candidate to hit that target."

Given that the diseases Brand mentions are all associated with aging, he says the tool now gives researchers an opportunity to test the free radical theory of aging, which has dropped in popularity in the field, in large part because of the failure of antioxidant therapies. "We can start to answer questions that scientists have puzzled about for 50 years in terms of the specifics of oxidative damage," he said. "We now have a precise tool to find out if the theory is correct. We can go into a biological system, see specifically what free radicals do and take preliminary steps to stop it."
Citation: Suppressors of Superoxide/H2O2 Production at Site IQ of Mitochondrial Complex I Protect Against Stem Cell Hyperplasia and Ischemia/Reperfusion Injury

DOI: 10.1016/j.cmet.2016.08.012

Other Buck researchers involved in the study include Renata L. S. Goncalves, Adam L. Orr, Akos A. Gerencser, Martin Borch Jensen, Simon Melov, Irina V. Perevoshchikova and Heinrich Jasper. Other collaborators include Leonardo Vargas, Carolina N. Turk, Jason T. Matzen, Victoria J. Dardov, H. Michael Petrassi, Shelly L. Meeusen, and Edward K. Ainscow of the Genomics Institute of the Novartis Research Foundation, San Diego, CA; and Yves T. Wang and Paul S. Brookes, the Department of Anaesthesiology, University of Rochester Medical Center, Rochester, New York, NY.

Acknowledgements: The work was supported by National Institutes of Health grants R01 AG033542 (M.D.B.), TL1 AG032116 (A.L.O.), GM100196 (H.J.), R01 HL127891 (P.S.B.) and The Ellison Medical Foundation grant AG-SS-2288-09 (M.D.B.). I.V.P. and R.L.S.G. received support from The Glenn Foundation- Buck Institute fellowship program. R.L.S.G. was also supported by the Brazilian Government through the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) eConselho de Nacional de Desenvolvimento Científico e Tecnológico programa Ciências Sem Fronteiras (CNPq-CSF). M.B.J. was supported by the Alfred Benzon Foundation.

Competing Financial Interests: L.V., C.N.T., J.T.M., V.J.D., H.M.P., S.L.M. and E.K.A. were employed by the Genomics Institute of the Novartis Research Foundation during the period of their contribution to this research. M.D.B. has consulted for Seahorse Bioscience. A.A.G. has a financial interest in Image Analyst Software.

About the Buck Institute for Research on Aging

The Buck Institute challenges the way we think about aging by approaching it as if it were a disease. We do not accept aging as inevitable decline. Our mission is to extend the healthy, vital years of life.

Our research is aimed at rendering chronic diseases as preventable, deferrable, curable or, at the least, manageable. Whenever possible, we want to restore function.

Buck scientists are pioneers. They work in a dynamic, collaborative environment to understand how normal aging contributes to conditions such as Alzheimer's and Parkinson's diseases, cancer, osteoporosis, arthritis, heart disease, diabetes, macular degeneration and glaucoma, among others.

We are an independent nonprofit organization working in an architectural landmark located in northern Marin County, California. For more information:

Buck Institute for Research on Aging

Related Heart Attack Articles:

Where you live could determine risk of heart attack, stroke or dying of heart disease
People living in parts of Ontario with better access to preventive health care had lower rates of cardiac events compared to residents of regions with less access, found a new study published in CMAJ (Canadian Medical Association Journal).
Activated T-cells drive post-heart attack heart failure
Chronic inflammation after a heart attack can promote heart failure and death.
ICU care for COPD, heart failure and heart attack may not be better
Does a stay in the intensive care unit give patients a better chance of surviving a chronic obstructive pulmonary disease (COPD) or heart failure flare-up or even a heart attack, compared with care in another type of hospital unit?
Heart attack treatment might be in your face
Researchers at the University of Cincinnati have received $2.4 million in federal funding to pursue research on a novel cell therapy that would repair heart damage using modified cells taken from the patient's own facial muscle.
Tissue engineering advance reduces heart failure in model of heart attack
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Study shows functional effects of human stem cell delivery to heart muscle after heart attack
Researchers delivered human stem cells seeded in biological sutures to the damaged heart muscles of rats following induced acute myocardial infarction and assessed the effects on cardiac function one week later.
Younger heart attack survivors may face premature heart disease death
For patients age 50 and younger, the risk of premature death after a heart attack has dropped significantly, but their risk is still almost twice as high when compared to the general population, largely due to heart disease and other smoking-related diseases The risk of heart attack can be greatly reduced by quitting smoking, exercising and following a healthy diet.
After the heart attack: Injectable gels could prevent future heart failure (video)
During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells in the heart.
Heart failure after first heart attack may increase cancer risk
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study today in the Journal of the American College of Cardiology.
1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25,000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr.

Related Heart Attack Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.